About LungXperience
LungXperience is a Healthcare company based in Wilmington (United States) founded in 2019. It delivers augmented reality-based educational tools for lung cancer awareness. It operates on a B2B model. Its focus areas include Medical Education, Augmented Reality Training and Cancer Education. Its competitors include The CareVoice, Mytonomy, CheckedUp, Docola and Medumo and 5 more; 6 of its 10 listed competitors have raised funding.
Company details
LungXperience delivers augmented reality-based educational tools for lung cancer awareness through providing healthcare solutions, medical education, augmented reality training, and cancer education. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Wilmington, United States
- SectorsHealthcare
- Website lungxperience.com
Competitors of LungXperience
LungXperience has 10 listed competitors in our database, 6 of them funded. They include The CareVoice, Mytonomy, CheckedUp, Docola and Medumo, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| thecarevoice.com | 2013 | Shanghai, China | $22M | – | A cloud-based platform for healthcare reviews and listings is operated. | |
| mytonomy.com | 2011 | Bethesda, United States | $42.79M | – | Cloud-based microlearning platform is utilized for patient education in hospitals. | |
| checkedup.com | 2011 | Miami, United States | – | – | Extending doctor patient relation beyond office walls | |
| doco.la | 2013 | Largo, United States | $300,000 | – | Allows doctors to create customizable Patient education material | |
| medumo.com | 2013 | Tempe, United States | $2.13M | – | Enables healthcare organizations to guide patients using automated just-in-time instructions and checklists | |
| mpirik.com | 2011 | Milwaukee, United States | $1.8M | 19 | Orthopedic care management platforms are provided for clinics and hospitals. | |
| skylight1.com | 1999 | San Diego, United States | $39.24M | – | Patient engagement platforms are provided for hospitals and administrators. | |
| evideon.com | 1993 | Grand Rapids, United States | – | 114 | Solution offering video content that engages, educates and entertains patients and families | |
| myrecovery.ai | 2015 | London, United Kingdom | – | – | App-based support for orthopaedic patients and healthcare professionals' care optimization. | |
| andorhealth.com | 2019 | Orlando, United States | – | – | Patient education platform is provided for health systems and hospitals. |
Detailed competitors of LungXperience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as LungXperience (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about LungXperience
LungXperience was founded in 2019.
LungXperience is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
LungXperience delivers augmented reality-based educational tools for lung cancer awareness through providing healthcare solutions, medical education, augmented reality training, and cancer education. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
LungXperience's top competitors include Mytonomy, The CareVoice and CheckedUp.